Author: S. C. Springmeyer1, J. R. Jett2; Medical, Biodesix, Boulder, CO, United States, National Jewish Health, Denver, CO, United States
Home
AABIP
Learn about the latest developments, research, and real world applications of Nodify Lung testing during our breakfast session at #AABIPCON.
PRESENTED BY:
Dr. Susan Garwood
Dr. David Silvestri
DATE/TIME:
Thursday, August 26, 6:30 a.m.
LOCATION:
Hilton Baltimore Inner Harbor
All #AABIPCON attendees welcome, no registration required.
Nodify Lung™ testing consists of two blood-based proteomic tests (the Nodify CDT™ & Nodify XL2® tests) to help physicians reclassify risk of cancer and aid in stratifying patients into distinct nodule management pathways: intervention or surveillance.
Biodesix Lung Reflex® testing consists of the GeneStrat® tumor profiling test and the VeriStrat® immune profiling test to provide physicians with timely molecular results to facilitate treatment decisions for patients with non-small cell lung cancer.
We provide biopharmaceutical companies with end-to-end diagnostic services inclusive of diagnostic research and feasibility, assay development, clinical trial testing, and commercialization of companion diagnostics.